icos-19-yn-1-ol | 144017-86-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: icos-19-yn-1-ol
• CAS: 144017-86-7
• 化学式: C₂₀H₃₈O
• 分子量: 294.521
• InChiKey: XNWWWZPUKCTUNR-UHFFFAOYSA-N

物化性质

• 沸点：
  393.3±15.0 °C(Predicted)
• 密度：
  0.866±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  21
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  icos-19-yn-1-ol 在 palladium on activated charcoal 氢氧化钾 、 四甲基乙二胺 、 氢气 、 氧气 、 溶剂黄146 、 三乙胺 、 copper(l) chloride 作用下， 以 乙醇 、 二氯甲烷 、 xylene 为溶剂， 反应 8.25h， 生成 (S)-1-(1,4-Dioxa-cyclotetratetracont-2-yl)-methanol
  参考文献：
  名称：

  Synthesis and thermotropic properties of macrocyclic lipids related to archaebacterial membranes

  摘要：

  Macrocyclic phospholipids containing 32-44 ring atoms were synthesized by a route involving a high-temperature Glaser oxidation as the key step. These lipids are analogous to mammalian phospholipids except a single extra carbon-carbon bond joins the chain termini. The new lipids offered, therefore, an opportunity to examine thermotropic properties of their membranes when the chains within a given molecule are unable to move independently of one another. It was concluded that chain ''tethering'' (a) raises the transition temperatures substantially for all but the shortest lipids, (b) lowers enthalpies of transition by, in part, reducing the number of gauche C-C linkages created during the melting process, and (c) lowers entropies of transition by impeding motional freedom with in the liquid-crystalline phase. Molecular mechanics calculations on the macrocyclic lipids are described briefly.

  DOI：

  10.1021/ja00068a017
• 作为产物：
  描述：

  2-[(11-bromoundecyl)oxy]tetrahydro-2H-pyran 在 正丁基锂 、 potassium tert-butylate 、 lithium 、 1,3-丙二胺 作用下， 生成 icos-19-yn-1-ol
  参考文献：
  名称：

  Menger, Frederic M.; Brocchini, Stephen; Chen, Xiangyang, Angewandte Chemie, 1992, vol. 104, # 11, p. 1542 - 1543

  摘要：

  DOI：

文献信息

• [EN] NUCLEOSIDE PRODRUGS AND USES RELATED THERETO<br/>[FR] PROMÉDICAMENTS NUCLÉOSIDIQUES ET LEURS UTILISATIONS
  申请人：UNIV EMORY

  公开号：WO2021035214A1

  公开（公告）日：2021-02-25

  Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ω-oxidation, such as ω -oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.

  揭示了具有改善代谢稳定性和口服生物利用度的非环核苷前药。一般来说，这些前药是非环核苷膦酸酯的衍生物，含有类似脂质的基团，可以增加口服吸收并在肝脏和血浆中提高稳定性。最好，类似脂质的基团可以抵抗酶介导的ω-氧化，例如细胞色素P450酶催化的ω-氧化。还揭示了非环核苷前药的药物配方。这些非环核苷前药及其药物配方可用于治疗病毒感染，如HIV感染，和/或病毒相关癌症，如HPV相关癌症。
• ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties
  作者：Nicole Pribut、Michael D’Erasmo、Madhuri Dasari、Kyle E. Giesler、Sabrina Iskandar、Savita K. Sharma、Perry W. Bartsch、Akshay Raghuram、Anatoliy Bushnev、Soyon S. Hwang、Samantha L. Burton、Cynthia A. Derdeyn、Adriaan E. Basson、Dennis C. Liotta、Eric J. Miller

  DOI：10.1021/acs.jmedchem.1c01083

  日期：2021.9.9

  of two FDA-approved prodrugs, both of which metabolize prematurely in the liver and/or plasma. This premature prodrug processing depletes significant fractions of each oral dose and causes toxicity in kidney, bone, and liver with chronic administration. Although TFV exalidex (TXL), a phospholipid-derived prodrug of TFV, was designed to address this issue, clinical pharmacokinetic studies indicated substantial

  替诺福韦 (TFV) 是许多针对 HIV/AIDS 患者的联合抗逆转录病毒疗法中的基石核苷酸逆转录酶抑制剂 (NtRTI)。由于细胞渗透性和口服生物利用度较差，TFV 作为 FDA 批准的两种前药之一施用，这两种前药都会在肝脏和/或血浆中过早代谢。这种过早的前药加工会消耗每次口服剂量的很大一部分，并在长期给药时引起肾脏、骨骼和肝脏毒性。尽管 TFV exalidex (TXL)（一种 TFV 的磷脂衍生前药）旨在解决这个问题，但临床药代动力学研究表明大量的肝提取，将 TXL 的临床开发转向 HBV。为了规避这种代谢缺陷，我们合成并评估了 ω 功能化的 TXL 类似物，其肝稳定性显着提高。这项工作导致了化合物21和23的鉴定，它们在人肝微粒体中表现出比 TXL 更长的t 1/2值、有效的体外抗 HIV 活性以及增强的体内药代动力学特性。
• NUCLEOSIDE PRODRUGS AND USES RELATED THERETO
  申请人：Emory University

  公开号：EP4017499A1

  公开（公告）日：2022-06-29
• Nucleoside Prodrugs and Uses Related Thereto
  申请人：Emory University

  公开号：US20220298185A1

  公开（公告）日：2022-09-22

  Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ω-oxidation, such as ω-oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.